Article
Medicine, Research & Experimental
Eric Zhuang, Edward Uchio, Michael Lilly, Xiaolin Zi, John P. Fruehauf
Summary: Docetaxel plus lycopene therapy showed effectiveness in advanced castrate resistant adenocarcinoma of prostate, with a 76.9% PSA response rate and a median survival of 35.1 months, indicating the potential value of this combination therapy.
BIOMEDICINE & PHARMACOTHERAPY
(2021)
Article
Urology & Nephrology
Ravi A. Madan, Fatima H. Karzai, Munjid Al Harthy, Daniel P. Petrylak, Joseph W. Kim, Philip M. Arlen, Inger Rosner, Marc R. Theoret, Lisa Cordes, Marijo Bilusic, Cody J. Peer, Nancy A. Dawson, Anna Couvillon, Amy Hankin, Moniquea Williams, Guin Chun, Helen Owens, Jennifer L. Marte, Min-Jung Lee, Yusuke Tomita, Akira Yuno, Jane B. Trepel, Sunmin Lee, Seth M. Steinberg, James L. Gulley, William D. Figg, William L. Dahut
Summary: The study evaluated the safety and efficacy of cabozantinib combined with docetaxel in mCRPC patients. Cabozantinib was found to be safely added to docetaxel treatment with potential enhanced efficacy. However, due to limited patient accrual, the phase 2 study was terminated early.
Article
Endocrinology & Metabolism
Soumyajit Roy, Christopher J. D. Wallis, Scott C. Morgan, Amar U. Kishan, Amy Tu Trinh Le, Julia Malone, Yilun Sun, Daniel E. Spratt, Fred Saad, Shawn Malone
Summary: This study analyzed the data from the ACIS study to determine if synchronous versus metachronous metastatic presentation is associated with survival and treatment response in docetaxel naive metastatic castrate resistant prostate cancer (mCRPC). The results showed that the stage of metastasis was not associated with disease progression, and there was no significant difference in the efficacy of treatment with docetaxel.
Article
Biochemistry & Molecular Biology
Juan Morote, Adriana Aguilar, Jacques Planas, Enrique Trilla
Summary: Castrate resistant prostate cancer (CRPC) refers to the continued progression of prostate cancer in an environment with very low serum testosterone concentration. The current definition is outdated and needs to be updated with more accurate imaging modalities and biochemical measurements to assess clinical progression and the castration environment.
Article
Oncology
Christoph Henkenberens, Thorsten Derlin, Frank Bengel, Tobias L. Ross, Markus A. Kuczyk, Frank A. Giordano, Gustavo R. Sarria, Leonard Christopher Schmeel, Hans Christiansen, Christoph A. J. von Klot
Summary: PSMA PET-guided RT could be a feasible treatment option for patients with oligometastatic mCRPC in delaying further systemic therapies, as shown in this study with a median bPFS of 12.0 months and a median SST-FS of 15.0 months.
FRONTIERS IN ONCOLOGY
(2021)
Review
Oncology
Ephraim E. Parent, Adam M. Kase
Summary: This review explores the use of targeted radionuclide therapy in the treatment of metastatic prostate cancer. Lu-177 PSMA-617 and (RaCl2)-Ra-223 are commonly used therapies, but there is a lack of guidance on how to best utilize these treatments. The article also introduces other less well-known targeted radionuclide therapies.
Article
Pharmacology & Pharmacy
Firas Almasri, Emmanuel H. Sakarya, Raffi Karshafian
Summary: This study demonstrates the potential of combining chemotherapy and therapeutic ultrasound-microbubble treatment to enhance radiotherapy in inducing cell death and apoptosis, as well as long-term tumor shrinkage, in an in vivo cancer model.
Article
Oncology
Priyanka H. Patel, Nina Tunariu, Daniel S. Levine, Johann S. de Bono, Rosalind A. Eeles, Vincent Khoo, Julia Murray, Christopher C. Parker, Angela Pathmanathan, Alison Reid, Nicholas van As, Alison C. Tree
Summary: Oligoprogression is poorly defined in current literature, and little is known about its significance in patients with hormone-resistant prostate cancer. This study found that nearly a third of patients on androgen receptor-targeted therapy for castration-resistant prostate cancer had oligoprogression. Patients with oligoprogression had better PSA response and longer duration on treatment compared to those with polyprogressive disease.
FRONTIERS IN ONCOLOGY
(2022)
Review
Oncology
Mahasha P. J. Perera, Patrick B. Thomas, Gail P. Risbridger, Renea Taylor, Arun Azad, Michael S. Hofman, Elizabeth D. Williams, Ian Vela
Summary: This review discusses the role of CAR-T cell therapy in men with metastatic castrate-resistant prostate cancer. Prostate cancer is the most commonly diagnosed solid-organ cancer in males worldwide. Men with metastatic castrate-resistant prostate cancer have limited treatment options, and current therapies are not curative. CAR-T cell therapy has shown success in the treatment of treatment-resistant hematological malignancies, and there are ongoing studies investigating its utility in solid tumors. However, preliminary clinical trials in men with prostate cancer have had limited efficacy, indicating the need for further research to enhance understanding and translation of this therapy.
Article
Food Science & Technology
Gisella Campanelli, Rabab Al Deabel, Anand Puaar, Lakshmi Sirisha Devarakonda, Prashanth Parupathi, Joyce Zhang, Noah Waxner, Ching Yang, Avinash Kumar, Anait S. Levenson
Summary: This study investigates the in vitro and in vivo anticancer effects of Gnetin C (GnC) alone and in combination with Enz against castrate-resistant prostate cancer (CRPC). The results demonstrate that GnC alone and combined with Enz effectively inhibit cell viability, clonogenic survival and migration, as well as the expression of AR and MTA1 in 22Rv1 cells.
MOLECULAR NUTRITION & FOOD RESEARCH
(2023)
Editorial Material
Oncology
Stephanie Gleicher, Baylee A. Porter, Disharee Nath, Guanqun Li, Rakesh Khanna, Hanan Goldberg, Marcin Kortylewski, Gennady Bratslavsky, Leszek Kotula
Summary: Nearly one third of men will have biochemical recurrence after localized prostate cancer treatment. Androgen deprivation therapy is a common treatment, but some patients may progress to a castrate resistant state. This review focuses on therapies and strategies targeting men with non-metastatic CRPC.
Article
Oncology
Sophie Peltekian, Shellyza Sajwani, Xiang Wang, Salmaan Kanji
Summary: The purpose of this study was to determine the incidence of febrile neutropenia (FN) and neutropenia in patients with castrate-resistant metastatic prostate cancer (mCRPC) receiving docetaxel and to identify predictors for FN. The results showed that the incidence of FN and neutropenia in patients receiving docetaxel for mCRPC was 25% and 33% respectively. Age and multiple comorbidities were identified as risk factors for FN.
SUPPORTIVE CARE IN CANCER
(2023)
Article
Multidisciplinary Sciences
Atefeh Deris, Mahdi Sohrabi-Haghighat
Summary: Patients with mCRPC are classified into three groups based on their response to Abiraterone treatment: best responder, responder, and non-responder. Drug-resistant cells may hinder successful outcomes in the latter two groups. To overcome this challenge, a combination of Docetaxel and Abiraterone is proposed to control both the overall cancer cell population and the drug-resistant subpopulation. Evolutionary Game Theory (EGT) is used as a mathematical modeling approach to study the competition and evolution of mCRPC cancer phenotypes.
Article
Oncology
Ivan de Kouchkovsky, Arpit Rao, Benedito A. Carneiro, Li Zhang, Catriona Lewis, Audrey Phone, Eric J. Small, Terence Friedlander, Lawrence Fong, Pamela L. Paris, Charles J. Ryan, Russell Z. Szmulewitz, Rahul Aggarwal
Summary: This study evaluated the safety and efficacy of ribociclib plus docetaxel in metastatic castration-resistant prostate cancer (mCRPC). The results showed that the combination treatment achieved a 6-month radiographic progression-free survival (rPFS) rate of 65.8% and a median rPFS of 8.1 months. Genomic profiling of circulating tumor cells (CTCs) suggested that nonamplified MYC was associated with longer rPFS.
CLINICAL CANCER RESEARCH
(2022)
Editorial Material
Radiology, Nuclear Medicine & Medical Imaging
Qiaoqiao Shu, Xianjun Li, Xi Chen, Yue Chen, Liang Cai
Summary: An 84-year-old man with prostate cancer underwent PET/CT for staging, which showed no significant abnormal tracer accumulation in Ga-68-prostate-specific membrane antigen PET/CT but elevated tracer uptake in F-18-OC (F-18-AlF-NOTA-octreotide) PET/CT at multiple sites. The patient chose to receive 1 cycle of Lu-177-DOTATATE peptide receptor radionuclide therapy and experienced radiographic tumor remission and improvement of clinical symptoms after just one cycle of treatment.
CLINICAL NUCLEAR MEDICINE
(2023)